Skip to main content
SpringerLink
Log in

Cancers du sein triples négatifs: Jusqu’où doit-on aller dans le bilan histologique?

  • Conference paper
Cancer du sein

  • 537 Accesses

Résumé

Cinq principaux sous-types moléculaires ont été identifiés à partir des données des puces d’expression d’analyse des carcinomes infiltrants de type canalaire: luminal A, luminal B, ERBB2, basal-like et normal-like. Les carcinomes basal-like sont caractérisés par l’absence d’expression des récepteurs aux estrogènes et à la progestérone et de ERBB2 et sont donc de ce fait »triples négatifs«. Toutefois, les carcinomes triples négatifs ne partagent pas tous les critères diagnostiques des basal-like et représentent un groupe plus large de tumeurs. Or, de nouvelles possibilités thérapeutiques basées sur une meilleure compréhension des caractéristiques biologiques des carcinomes basal-like sont en développement pour adapter la prise en charge thérapeutique des patientes. Comme cette entité a été identifiée à partir des données des puces d’expression transcriptomique inaccessible en routine et que de nouvelles avancées thérapeutiques de ces tumeurs deviennent disponibles, il est nécessaire de pouvoir les identifier en pratique clinique de façon simple et reproductible.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Perou CM, Sorlie T, Eisen MB et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747–752

    Article  PubMed  CAS  Google Scholar 

  2. Sorlie T, Perou CM, Tibshirani R et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98: 10869–10874

    Article  PubMed  CAS  Google Scholar 

  3. Sorlie T, Tibshirani R, Parker J et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS 100: 8418–8423

    Article  PubMed  CAS  Google Scholar 

  4. Sotiriou C, Wirapati P, Loi S et al. (2006) Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis. J Natl Cancer Inst 98: 262–272

    Article  PubMed  CAS  Google Scholar 

  5. Bertucci F, Finetti P, Cervera N et al. (2006) Gene Expression Profiling Shows Medullary Breast Cancer Is a Subgroup of Basal Breast Cancers. Cancer Res 66:4636–4644

    Article  PubMed  CAS  Google Scholar 

  6. Kreike B, van Kouwenhove M, Horlings H et al. (2007) Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 9: R65

    Article  PubMed  Google Scholar 

  7. Nielsen TO, Hsu FD, Jensen K et al. (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367–574

    Article  PubMed  CAS  Google Scholar 

  8. van de Rijn M, Perou CM, Tibshirani R et al. (2002) Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome. Am J Pathol 161: 1991–1996

    Article  PubMed  Google Scholar 

  9. Lakhani SR, van de Vijver MJ, Jacquemier J et al. (2002) The Pathology of Familial Breast Cancer: Predictive Value of Immunohistochemical Markers Estrogen Receptor, Progesterone Receptor, HER-2, and p53 in Patients With Mutations in BRCA1 and BRCA2. J Clin Oncol 20: 2310–2318

    Article  PubMed  CAS  Google Scholar 

  10. Badve S, Dabbs DJ, Schnitt SJ et al. (2011) Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 24: 157–167

    Article  PubMed  Google Scholar 

  11. Foulkes WD, Smith IE, Reis-Filho JS (2011) Triple-negative breast cancer. N Engl J Med 363: 1938–1948

    Article  Google Scholar 

  12. Weigelt B, Kreike B, Reis-Filho JS (2009) Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat 117: 273–280

    Article  PubMed  CAS  Google Scholar 

  13. Jacquemier J, Padovani L, Rabayrol L et al. (2005) Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol 207: 260–268

    Article  PubMed  CAS  Google Scholar 

  14. Vincent-Salomon A, Gruel N, Lucchesi C et al. (2007) Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 9: R24

    Article  PubMed  Google Scholar 

  15. Rodriguez-Pinilla SM, Rodriguez-Gil Y, Moreno-Bueno G et al. (2007) Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study. Am J Surg Pathol 31: 501–508

    Article  PubMed  Google Scholar 

  16. Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26: 2568–2581

    Article  PubMed  Google Scholar 

  17. Azoulay S, Lae M, Freneaux P et al. (2005) KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol 18: 1623–1631

    PubMed  CAS  Google Scholar 

  18. Lae M, Freneaux P, Sastre-Garau X et al. (2009) Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum. Mod Pathol 22: 291–298

    Article  PubMed  CAS  Google Scholar 

  19. Farmer P, Bonnefoi H, Becette V et al. (2005) Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24: 4660–4671

    Article  PubMed  CAS  Google Scholar 

  20. Bergamaschi A, Kim YH, Wang P et al. (2006) Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and geneexpression subtypes of breast cancer. Genes Chromosomes Cancer 45: 1033–1040

    Article  PubMed  CAS  Google Scholar 

  21. Chin K, DeVries S, Fridlyand J et al. (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10: 529–541

    Article  PubMed  CAS  Google Scholar 

  22. Foulkes WD, Stefansson IM, Chappuis PO et al. (2003) Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer. JNCI Cancer Spectrum 95:1482–1485

    Article  CAS  Google Scholar 

  23. Turner NC, Reis-Filho JS (2006) Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25: 5846–5853

    Article  PubMed  CAS  Google Scholar 

  24. Turner NC, Reis-Filho JS, Russell AM et al. (2007) BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26: 2126–2132

    Article  PubMed  CAS  Google Scholar 

  25. Reis-Filho JS, Tutt AN (2008) Triple negative tumours: a critical review. Histopathology 52: 108–118

    Article  PubMed  CAS  Google Scholar 

  26. Carey LA, Dees EC, Sawyer L et al. (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329–2334

    Article  PubMed  CAS  Google Scholar 

  27. Rouzier R, Perou CM, Symmans WF et al. (2005) Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy. Clin Cancer Res 11: 5678–5685

    Article  PubMed  CAS  Google Scholar 

  28. Ashworth A (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26: 3785–3790

    Article  PubMed  CAS  Google Scholar 

  29. Fong PC, Boss DS, Yap TA et al. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123–134

    Article  PubMed  CAS  Google Scholar 

  30. Lord CJ, Ashworth A (2008) Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 8: 363–369

    Article  PubMed  CAS  Google Scholar 

  31. Martin SA, Lord CJ, Ashworth A (2008) DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev 18: 80–86

    Article  PubMed  CAS  Google Scholar 

  32. Turner N, Tutt A, Ashworth A (2005) Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 5: 388–393

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. A. Vincent-Salomon
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag France, Paris

About this paper

Cite this paper

Vincent-Salomon, A. (2012). Cancers du sein triples négatifs: Jusqu’où doit-on aller dans le bilan histologique?. In: Cancer du sein. Springer, Paris. https://doi.org/10.1007/978-2-8178-0245-9_36

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0245-9_36

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0244-2

  • Online ISBN: 978-2-8178-0245-9

Publish with us

Policies and ethics

Search

Navigation